Life Sciences Masters™ 2026 IPW Studios, Ashburn, VA
November 9-10, 2026
Hero background

Event Session

The Strategic Applicant: Prosecuting Life Sciences Patents for What Comes Next *

November 9, 2026 @ 4:00 PM EST

4:00 PM ET
November 9, 2026

The Strategic Applicant: Prosecuting Life Sciences Patents for What Comes Next *

View Session Speakers

CLEWhen a life sciences patent application is filed, no one knows exactly what the future holds. The invention may ultimately support a blockbuster product, become central to a collaboration or licensing transaction, increase the value of an acquisition target, provide negotiating leverage, or become the patent at the center of high-stakes litigation years later. Strategic prosecution therefore requires more than obtaining an allowance; it requires preserving options for whatever comes next.

This panel will examine how sophisticated applicants prosecute life sciences patents with that uncertain future in mind. Panelists will discuss building applications and claim sets with flexibility, managing continuation strategies, using examiner interviews effectively, navigating restrictions, RCEs, appeals and supervisory involvement, and deciding when faster prosecution makes strategic sense. The panel will also explore how choices made during prosecution can preserve—or unnecessarily surrender—future claim scope, transaction value and enforcement positions. The objective is not simply to obtain patents, but to build durable portfolios capable of supporting opportunities and surviving challenges that cannot be fully anticipated when prosecution begins.

Survey

https://www.surveymonkey.com/r/The-Strategic-Applicant

Materials

Patent Portfolio Economics: Balancing Quality, Cost and Market Coverage

The Future of Genus Patenting Strategies for Antibodies Post-Amgen

CAFC Kills Cancer Treatment Patent Claims Due to Lack of Written Description, Enablement

CAFC Dodges Key Issues in Reversing District Court Finding for Google on Prosecution Laches

Is AI the Answer for Meeting Patent Enablement Requirements?



Add to Calendar

Session Speakers

Sarah Fashena, Ph.D.

VP, Head of Intellectual Property Strategy

Ascidian Therapeutics, Inc.

Allison Gilder, Ph.D.

Partner

Foley Hoag

Colin Heitzmann

Vice President of Intellectual Property

Travere Therapeutics

Gene Quinn, CEO and Founder of IPWatchdog.

Gene Quinn

Founder & CEO

IPWatchdog, Inc.

John Rearick, Ph.D.

Partner

Cooley LLP